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Purpose: Given the limited salvage options for in-stent restenosis (ISR) of drug-eluting stents
(DES), our high-volume cardiac catheterization laboratory has been performing intracoronary
brachytherapy (ICBT) in patients with recurrent ISR of DES. This study analyzes their baseline
characteristics and assesses the safety/toxicity of ICBT in this high-risk population.
Methods and materials: A retrospective analysis of patients treated with ICBT between September
2012 and December 2014 was performed. Patients with ISR twice in a single location were
eligible. Procedural complications included vessel dissection, perforation, tamponade, slow/absent
blood ﬂow, and vessel closure. Postprocedural events included myocardial infarction, coronary
artery bypass graft, congestive heart failure, stroke, bleeding, thrombosis, embolism, dissection,
dialysis, or death occurring within 72 hours. A control group of patients with 2 episodes of ISR at 1
location who underwent percutaneous coronary intervention without ICBT was identiﬁed.
Unpaired t tests and c2 tests were used to compare the groups.
Results: There were 134 (78%) patients in the ICBT group with 141 treated lesions and 37 (22%)
patients in the control group. There was a high prevalence of hyperlipidemia (>95%), hypertension
(>95%), and diabetes (>50%) in both groups. The groups were well-balanced with respect to age,
sex, and pre-existing medical conditions, with the exception of previous coronary artery bypass graft
being more common the ICBT group. Procedural complication rates were low in the control and
ICBT groups (0% vs 4.5%, PZ .190). Postprocedural event rates were low (<5%) in both groups.
Readmission rate at 30 days was 3.7% in the ICBT group and 5.4% in the control group (PZ .649).
Conclusions: This is the largest recent known series looking at ICBT for recurrent ISR of DES.
ICBT is a safe treatment option with similarly low rates (<5%) of procedural and postprocedural
complications compared with percutaneous coronary intervention alone. This study establishes the
safety of ICBT in a high-risk patient cohort.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Conﬂicts of Interest: None.
* Corresponding author. Department of Radiation Oncology, Mount Sinai Hospital, 1184 5th Avenue, Box 1236, New York, NY 10029.
E-mail addresses: Richard.Bakst@mountsinai.org (R. Bakst).
http://dx.doi.org/10.1016/j.adro.2015.12.002
2452-1094/Copyright  2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Advances in Radiation Oncology: JanuaryeMarch 2016 Intracoronary brachytherapy 5Introduction
Restenosis after percutaneous coronary revasculariza-
tion, deﬁned as 50% or greater reduction in luminal
diameter at the time of follow-up angiography, remains an
important clinical issue. Previous studies have demon-
strated restenosis rates ranging from 40% to 50% after
balloon angioplasty alone.1 With the introduction of bare
metal stents (BMS), the rate of restenosis decreased to
about 20%.2,3
It was hypothesized that intracoronary irradiation may
reduce vascular smooth muscle proliferation and neo-
intimal proliferation after a balloon overstretch procedure,
which could prevent or reduce in-stent restenosis. Several
studies demonstrated signiﬁcant reduction in the percent
area of restenosis with endovascular radiation in animal
models.4,5 Intracoronary radiation therapy was eventually
approved for use as an adjunctive therapy in the setting of
in-stent restenosis (ISR) in BMS, with multiple trials
demonstrating improved rates of angiographic restenosis,
target lesion revascularization, and major cardiac events.6,7
In the early 2000s, the drug-eluting stent (DES) was
introduced and further lowered the rate of target lesion
revascularization by 50% or more compared with BMS.8-10
Two randomized trials were subsequently conducted to
compare the efﬁcacy of intracoronary brachytherapy
(ICBT) to paclitaxel and sirolimus drug-eluting stents in
the setting of ISR of a BMS. Both trials demonstrated
signiﬁcantly lower rates of restenosis at 9 months with
DES.9,11 As a result, the use of ICBT signiﬁcantly
decreased across the United States.
However, the rate of ISR in DES remains signiﬁcant,
with some studies demonstrating rates of up to 20%.12
Patients who fail DES have limited salvage options and
often multiple medical comorbidities, making them
inherently high risk. Additionally, patients who fail DES
multiple times in the same location may already have
multiple stent layers in place making further interventions
more challenging and high risk. After very preliminary
data demonstrated some efﬁcacy, our high-volume
cardiac catheterization laboratory reinitiated ICBT for
patients with recurrent ISR of DES.13 In our current
series, we report on the baseline characteristics of this
high-risk patient population and the safety of the ICBT
procedure before initiating any prospective or randomized
trials of ICBT for ISR of DES.
Methods and materials
A retrospective analysis of patients treated with ICBT
between September 2012 and December 2014 was per-
formed. Patients who developed ISR twice in a single
location were eligible for ICBT. Patients with prior ICBT
and/or external beam radiation near the heart were not
eligible. A control group of all patients who also had 2episodes of ISR in 1 location and underwent percutaneous
coronary intervention (PCI) without ICBT treated over
the same period was retrospectively established. Although
these patients were eligible for ICBT based on their dis-
ease characteristics, ICBT has not yet been consistently
incorporated into the treatment paradigm for recurrent
ISR of DES. Baseline demographics and pertinent medi-
cal histories were recorded for all patients.
All patients who received ICBT were treated with the
Novoste Beta-Cath 3.5F System after PCI. A stronium-
90/yttrium-90 isotope was used for the treatment system.
The principal radiation emission was beta particles with
energies up to 2.27 MeV and a radioactive half-life of
28.8 years. Source lengths of 40 and 60 mm were used,
which was determined based on the length of the target
lesion. The target vessel received 18.4 or 23 Gy at a depth
of 2 mm from the center of the source. The prescribed
dose was determined by the vessel diameter. Dwell times
typically ranged from 200 to 300 seconds and were
determined by both the source length and vessel diameter.
After PCI, a delivery catheter with radiopaque markers
was ﬁrst inserted and localized under ﬂuoroscopy. Once it
was properly positioned, the selected delivery device was
then attached, and the source was sent by hydraulic pres-
sure. A timer was manually started when the source
reached the designated location. After the planned dwelling
time elapsed, the source was retracted, and the delivery
catheter was removed from the patient. A room survey was
performed to ensure no isotope remained inside the patient
or outside the delivery system. Overall, the ICBT proce-
dure was generally completed within 10 minutes. Figure 1
illustrates the steps of the ICBT procedure.
Procedural complications occurring during PCI or the
ICBT procedure and postprocedural events occurring
within 72 hours after PCI were recorded. Readmission rate
for any cause at 30 days was also recorded. Unpaired t tests
and c2 tests were used to compare the ICBT and control
groups. Institutional review board approval was obtained.Results
There were 134 (78%) patients in the ICBT group and
37 (22%) in the control group. Six patients in the ICBT
group had lesions that were longer than the maximum
60-mm train length and were treated with 2 sources
consecutively. In these cases, there was a small area of
overlap (<5 mm) with adequate proximal and distal
margins. Two patients in the ICBT group were treated to
2 separate lesions on different dates in separate pro-
cedures. Additionally, 5 patients were treated to 2 sepa-
rate lesions in the same procedure, for a total of 141
treated lesions in the ICBT group.
Baseline characteristics and comorbidities for both
groups are listed in Table 1. The ICBT and control
groups were well-balanced with respect to age, sex, and
Figure 1 Step-by-step ICBT procedure. DES, drug-eluting stents; ICBT, intracoronary brachytherapy; PCI, percutaneous coronary
intervention.
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vious coronary artery bypass graft being more common the
ICBT group. Before PCI, the majority of patients in both the
ICBT and control groups presented with stable angina
(55.2% vs 54.1%, PZ .899) or unstable angina (31.3% vs
43.2%, PZ .176). A source length of 60 mm was used for
81 of the 141 lesions treated with ICBT (57.4%). The
prescribed dose was 23 Gy for 52.1% of lesions.
Procedural complications included grade 3 vessel
dissection, perforation, tamponade, slow or absent bloodﬂow, side branch closure, and vessel closure, which are
listed in Table 2. The overall procedural complication
rates were low for both groups (0% control group vs 4.5%
ICBT group, P Z .190).
Postprocedural events included myocardial infarction,
coronary artery bypass graft, congestive heart failure,
stroke, bleeding, thrombosis, embolism, dissection, dial-
ysis, or death occurring within 72 hours after PCI and are
listed in Table 3. Five patients (3.7%) in the ICBT group
experienced a myocardial infarction compared with none
Table 1 Baseline characteristics and comorbidities
Control
n Z 37 (%)
ICBT
n Z 134 (%)
P value
Age, median (years) 61 65.5 .080
Male gender 25 (67.6) 100 (74.6) .391
Pre-existing medical
conditions
Hyperlipidemia 36 (97.3) 134 (100.0) .056
Hypertension 37 (100.0) 133 (99.3) .598
Diabetes mellitus 24 (64.9) 79 (59.0) .516
Previous MI 10 (27.0) 59 (44.0) .062
Previous CABG 9 (24.3) 62 (46.3) .017
Stroke 6 (16.2) 20 (14.9) .847
CABG, coronary artery bypass graft; ICBT, intracoronary brachy-
therapy; MI, myocardial infarction.
Table 3 Postprocedural events occurring within 72 hours
after PCI
Control
n Z 37 (%)
ICBT
n Z 134 (%)
P value
MI 0 (0) 5 (3.7) .233
CABG 0 (0) 0 (0)
CHF 0 (0) 0 (0)
Stroke 0 (0) 0 (0)
Bleeding 0 (0) 0 (0)
Thrombosis 0 (0) 0 (0)
Embolism 0 (0) 0 (0)
Dissection 0 (0) 0 (0)
Dialysis 1 (2.7) 0 (0) .056
Death 0 (0) 0 (0)
CABG, coronary artery bypass graft; CHF, congestive heart failure;
ICBT, intracoronary brachytherapy; MI, myocardial infarction; PCI,
percutaneous coronary intervention.
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control group required dialysis compared with none in the
ICBT group (P Z .056). No additional events were
recorded. Readmission rate for any cause at 30 days was
low in both the ICBT (3.7%) and control (5.4%) groups
(P Z .649).
Discussion
Although the introduction of DES has markedly
reduced the rate of ISR compared with BMS, a signiﬁcant
number of patients still develop ISR of DES.12 These
patients are often very high-risk cardiac patients who have
failed standard therapies and have limited salvage options.
Furthermore, because patients have multiple levels
of stents within 1 lesion, additional procedures carry
increased risk. To address this clinical issue, our high-
volume cardiac catheterization laboratory is investi-
gating the role of ICBT in patients with recurrent ISR of
DES. Our study examines the baseline characteristics of
this patient population and assesses the safety and toxicity
of the ICBT procedure. To our knowledge, this study
represents the largest recent series looking at ICBT in the
setting of ISR of DES.Table 2 Procedural events
Control
n Z 37 (%)
ICBT
n Z 134 (%)
P value
Grade 3 vessel
dissection
0 (0) 1 (2.2) .598
Perforation 0 (0) 2 (1.5) .455
Tamponade 0 (0) 0 (0)
Slow or absent blood
ﬂow
0 (0) 3 (2.2) .359
Side branch closure 0 (0) 1 (0.7) .598
Vessel closure 0 (0) 0 (0)
ICBT, intracoronary brachytherapy.As expected, our results show a high prevalence of
comorbid conditions in the ICBT cohort, demonstrating
that this is an inherently high-cardiac-risk patient popula-
tion. Still, the ICBT procedure was a well-tolerated treat-
ment with very low rates of procedural and postprocedural
events. Additionally, comparing the ICBT group with a
control group with similarly high rates of comorbid con-
ditions, there was no signiﬁcant difference in procedural or
postprocedural event rates. These results demonstrate that
ICBT is a safe treatment option, even in a high-risk patient
population in which acute events represent a signiﬁcant
cause of morbidity, and may have a role as salvage therapy
for patients with recurrent ISR of DES. We believe this
study supplies the safety data needed to initiate a pro-
spective trial within our institution to assess the efﬁcacy of
ICBT for treatment of ISR of DES.
The safety of the intracoronary brachytherapy procedure
was previously documented by a German group in 2000.
With the Novoste Beta-Cath system, ICBT was used to
treat de novo lesions, restenosis without stents, and in-stent
restenosis. Ninety-two patients with 104 lesions were
treated, with doses ranging from 14 to 20 Gy. There were
no acute complications including procedure-related deaths,
infarcts, or stent thrombosis.14 Another group from the
Netherlands published its experience with ICBT in 2000.
From that series of more than 250 patients treated with
ICBT after percutaneous transluminal coronary angio-
plasty, the group found that the integration of vascular
brachytherapy in the catheterization laboratory was both
feasible and safe.15
In 2001, Leon et al published a multicenter random-
ized study examining the safety and efﬁcacy of intra-
coronary gamma radiation with iridium-192 in the setting
of ISR of BMS. Patients were randomized to conventional
interventional techniques, such as balloon dilation, fol-
lowed by catheter based delivery of iridium-192 or a
nonradioactive placebo. Early events including death,
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the target lesion occurring within 30 days from the pro-
cedure were recorded. About 5% of patient in the ICBT
group experienced an early complication. Compared with
the control group, patients in the ICBT group had a lower
composite rate of death, myocardial infarction, emergency
bypass surgery, and target vessel revascularization (28%
vs 43.8%, P Z .02) at a follow-up of 9 months.6
Although our data demonstrates similar rates of proce-
dural and postprocedural events, our patients failed
DES and likely represent a more high-risk population.
Additionally, our treatment technique with a strontium
isotope delivers a different type of radiation with less
penetration, which should lower the risk of treatment-
related complications.
There are few studies that have examined the efﬁcacy
of ICBT in the setting of ISR of DES. An observational
series by Torguson et al in 2006 compared outcomes of
patients with ISR of DES who underwent vascular
brachytherapy (n Z 61) or repeat DES placement
(n Z 50). In this series, there were no procedural or in-
hospital events, again demonstrating the safety of the
ICBT procedure. At 8 months’ follow-up, target vessel
revascularization rates were 10% and 18%, respectively
(P Z not signiﬁcant). However, there were signiﬁcantly
fewer major adverse cardiac events in the vascular
brachytherapy group (10% vs 24%, P Z .044).16
Another observational series by Bonello et al in 2008
demonstrated a target lesion revascularization rate of
11% and major adverse cardiac event rate of 26% at a
follow-up of 12 months after ICBT.17 These studies
were limited, however, by their retrospective nature and
small sample sizes.
More recently, a meta-analysis comparing percuta-
neous treatment strategies for ISR of BMS and DES was
published by Siontis et al. Twenty-seven trials with 5923
patients were included, and the primary outcome was
percent diameter stenosis at angiographic follow-up. PCI
with everolimus-eluting stents was found to be the most
effective treatment for ISR, followed by drug-coated
balloons, other drug-eluting stents, vascular brachyther-
apy, and bare metal stents. Balloon angioplasty and
rotablation were the least effective treatment modalities.
Of note, fewer than 40% of patients included in this
analysis had ISR of DES. Our cohort of patients with
recurrent ISR of DES likely represents a more high-risk
population based on both pre-existing comorbidities as
well as the presence of multiple stent layers at the time
of PCI.18
This study represents the largest recent known
series examining the use of ICBT for patients with
recurrent ISR of DES and the safety of the ICBT
procedure in this high-risk population. There are inherent
limitations to the retrospectively established control
group, with possible bias introduced when selecting
patients to receive ICBT. Additionally, although acutetoxicity represents a major cause of morbidity, there is a
lack of data on potential long-term complications asso-
ciated with ICBT. Still, however, our current results
demonstrate that ICBT is a safe and well-tolerated pro-
cedure in a high-cardiac-risk patient population. We
believe that further investigation into the efﬁcacy of ICBT
as a form of salvage therapy for recurrent ISR of DES is
warranted.Conclusions
In-stent restenosis of DES is an important clinical
issue. Intracoronary brachytherapy is a safe and well-
tolerated treatment option that may serve as a form of
salvage therapy for high-risk patients with recurrent ISR
of DES. Additional investigation into the efﬁcacy of
ICBT in this setting is warranted.References
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